# Sirt6 promotes tumor growth and suppresses immune surveillance

**Authors:** Yan Wang, Yu Song, Xianqin Song, Nanyang Zhang, Kehua Fang, Xiaotian Chang

PMC · DOI: 10.1186/s12935-025-04125-x · Cancer Cell International · 2026-01-13

## TL;DR

This study shows that Sirt6 promotes tumor growth by suppressing immune responses and increasing M2 macrophage polarization.

## Contribution

The study reveals a novel mechanism by which Sirt6 activates Lao1 to suppress immune surveillance and promote tumor progression.

## Key findings

- Sirt6 activator UBCS039 increases tumor size and alters immune-related cytokine levels in mice.
- Sirt6 promotes M2 macrophage polarization via upregulation of Lao1 in tumor tissues.
- Sirt6 reduces IFN-γ and increases PD-L1 and PD-1, contributing to immune suppression.

## Abstract

Many studies have reported increased Sirt6 expression and activity in many tumor tissues, and the expression level is inversely linked to overall patient survival. This study explored how Sirt6 affects tumor growth and immune surveillance.

UBCS039, a selective Sirt6 activator, was dissolved in dimethyl sulfoxide (DMSO) and intraperitoneally administered to BALB/c-nude mice. These mice were then given injections of human tumor-derived HeLa, MB-231, Lm-3, or Hcc827 cells to establish a tumor-bearing model by routine methods.

Compared with tumor-bearing mice pretreated with DMSO or PBS, the mice pretreated with UBCS039 showed larger tumors. The levels of granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-10, adenosine (ADO) and NK cells were elevated in the peripheral blood of UBCS039-pretreated mice, and the IFN-γ level was decreased. Increased expression levels of Sirt6, PD-L1, NF-κB, and PD-1 were detected in the tumor tissues of UBCS039-pretreated mice. A greater abundance of M2 macrophages, also termed tumor-associated macrophages (TAMs), was observed in UBCS039-pretreated mouse tumors. Moreover, upregulation of novel Lao1 (interleukin 4-induced 1, IL4I1), which is known to control M2 polarization, was specifically detected in tumor tissues from UBCS039-treated mice via transcriptomic analysis and was verified by real-time PCR and western blotting. UBCS039 also stimulated M0-type and M1-type macrophage polarization to the M2-type phenotype in vitro, and Sirt6 and Lao1 expression increased during this process.

Sirt6 can increase ADO, PD-L1 and PD-1 levels; decrease IFN-γ levels; and promote M2 polarization through the upregulation of Lao1 expression, which increases tumor growth by suppressing immune surveillance.

The online version contains supplementary material available at 10.1186/s12935-025-04125-x.

## Linked entities

- **Genes:** SIRT6 (sirtuin 6) [NCBI Gene 51548], Lao1 (L-amino acid oxidase 1) [NCBI Gene 100470], CD274 (CD274 molecule) [NCBI Gene 29126], PDCD1 (programmed cell death 1) [NCBI Gene 5133], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], IL4I1 (interleukin 4 induced 1) [NCBI Gene 259307]
- **Proteins:** CSF2 (colony stimulating factor 2), IL10 (interleukin 10), IFNG (interferon gamma)
- **Chemicals:** UBCS039 (PubChem CID 2803797), Dimethyl sulfoxide (DMSO) (PubChem CID 679)
- **Diseases:** tumor (MONDO:0005070)

## Full-text entities

- **Genes:** SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}
- **Diseases:** tumor (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12809971/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12809971/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12809971/full.md

---
Source: https://tomesphere.com/paper/PMC12809971